Save for clinic
📖 Full analysis: Desktop version — complete efficacy tables, safety detail, subgroup data, and clinical implications
🎯 Clinical Bottom Line
Adding atezolizumab to nab-paclitaxel improved progression-free survival in first-line metastatic TNBC, with the largest benefit in PD-L1–positive patients. However, OS did not reach significance in the ITT population, and the accelerated FDA approval was subsequently withdrawn. Pembrolizumab + chemotherapy (KEYNOTE-355, CPS ≥10) is now the preferred first-line immunotherapy.
Key Result 1: PFS, ITT — 7.2 vs 5.5 mo, HR 0.80 (95% CI 0.69–0.92; P=0.002) Key Result 2: PFS, PD-L1+ — 7.5 vs 5.0 mo, HR 0.62 (95% CI 0.49–0.78; P<0.001) Key Result 3: OS, ITT — 21.3 vs 17.6 mo, HR 0.84 (95% CI 0.69–1.02; P=0.08, not significant) Key Result 4: OS, PD-L1+ (descriptive) — 25.0 vs 15.5 mo, HR 0.62 (95% CI 0.45–0.86; not formally tested)
Safety Signal: Immune-related AEs of special interest: any grade 57.3% vs 41.8%; grade 3/4: 7.5% vs 4.3%. Treatment-related deaths: 3 vs 1.
✅ Patient Eligibility
Must Have:
- Triple-negative breast cancer (metastatic or unresectable locally advanced)
- First-line — no prior chemo or targeted therapy for metastatic TNBC
- Tumor specimen for PD-L1 testing (SP142 assay)
- ECOG 0–1, measurable disease per RECIST v1.1
Cannot Have:
- Untreated CNS disease
- History of autoimmune disease
- Prior immune checkpoint inhibitor therapy
- Recent systemic immunostimulatory agent or immunosuppressive medications
💊 Dosing Quick Guide
Experimental Regimen
Atezolizumab: 840 mg IV days 1 and 15 q28d Nab-paclitaxel: 100 mg/m² IV days 1, 8, 15 q28d Duration: Until progression or unacceptable toxicity
Control Regimen
Placebo IV days 1 and 15 + nab-paclitaxel (same dose/schedule)
Key Dose Modifications [2]
- Hold atezolizumab for grade 3–4 immune-related AEs; permanently discontinue for grade 4 non-endocrine irAEs
- Nab-paclitaxel dose reductions per standard practice for neutropenia and neuropathy
- Monitor thyroid function, LFTs, and for signs of pneumonitis throughout treatment
Mechanism: Atezolizumab is a PD-L1 inhibitor that blocks PD-L1/PD-1 and PD-L1/B7.1 interactions, restoring T-cell antitumor immunity [2].
⚠️ Safety Snapshot
| Grade 3/4 Toxicities | Atezo + NabP (n=452) | Placebo + NabP (n=438) |
|---|---|---|
| Neutropenia | 37 (8.2%) | 36 (8.2%) |
| Peripheral neuropathy | 25 (5.5%) | 12 (2.7%) |
| Nausea | 5 (1.1%) | 8 (1.8%) |
| Pyrexia | 3 (0.7%) | 0 |
| Alopecia | 3 (0.7%) | 1 (0.2%) |
⚠️ Immune-related AEs of special interest: Any grade 57.3% vs 41.8%; Grade 3/4: 7.5% vs 4.3% ⚠️ Hypothyroidism (immune-related): 17.3% vs 4.3% (all grade 1–2) ⚠️ Pneumonitis: 3.1% vs 0.2% (1 grade 3/4 event in atezo arm)
Key safety metrics:
- Treatment-related deaths: 3 vs 1
- Fatal AEs: 6 (1.3%) vs 3 (0.7%)
- Serious AEs: 103 (22.8%) vs 80 (18.3%)
- Discontinuations due to AE (any agent): 15.9% vs 8.2%
📊 Key Numbers
Median follow-up: 12.9 months
| Outcome (Population) | Atezo + NabP | Placebo + NabP | HR (95% CI) | p-value |
|---|---|---|---|---|
| PFS (ITT, N=902) | 7.2 mo | 5.5 mo | 0.80 (0.69–0.92) | P=0.002 |
| PFS (PD-L1+, N=369) | 7.5 mo | 5.0 mo | 0.62 (0.49–0.78) | P<0.001 |
| OS (ITT) | 21.3 mo | 17.6 mo | 0.84 (0.69–1.02) | P=0.08 (NS) |
| OS (PD-L1+; descriptive) | 25.0 mo | 15.5 mo | 0.62 (0.45–0.86) | Not tested |
| ORR (ITT) | 56.0% | 45.9% | OR 1.52 (1.16–1.97) | P=0.002 |
| ORR (PD-L1+) | 58.9% | 42.6% | OR 1.96 (1.29–2.98) | P=0.002 |
| DOR (ITT) | 7.4 mo | 5.6 mo | 0.78 (0.63–0.98) | — |
🔬 Key Comparator Context
| Trial | Regimen | Population | Primary Endpoint | Key Result | Ref |
|---|---|---|---|---|---|
| IMpassion130 | Atezo + nab-paclitaxel | 1L mTNBC | PFS (inv) | mPFS 7.2 vs 5.5 mo; HR 0.80 | [1] |
| KEYNOTE-355 | Pembro + chemo | 1L mTNBC, CPS ≥10 | PFS & OS | mOS 23.0 vs 16.1 mo; HR 0.73 (CPS ≥10) | [4] |
| IMpassion131 | Atezo + paclitaxel | 1L mTNBC | PFS | mPFS 5.7 vs 5.6 mo; HR 0.82 (NS) | [5] |
Cross-trial comparisons are limited by differences in populations, designs, and endpoints.
🔍 Subgroups to Watch
PD-L1 positive: HR 0.64 (95% CI 0.51–0.80) — benefit concentrated here PD-L1 negative: HR 0.95 (95% CI 0.79–1.15) — no meaningful PFS benefit Bone metastases: Yes: HR 1.02 (95% CI 0.79–1.31) — no benefit observed Lymph node–only disease: HR 0.44 (95% CI 0.24–0.83) — largest benefit, small subgroup Age ≥65 yr: HR 0.69 (95% CI 0.51–0.94) — numerically favorable
Subgroup analyses were not powered for formal comparisons. Results are hypothesis-generating.
📋 Regulatory Status
| Region | Status |
|---|---|
| FDA | ⚠️ Accelerated approval WITHDRAWN (Aug 2021). Atezolizumab no longer indicated for mTNBC. |
| EMA | Authorization withdrawn for this indication |
⚠️ Verify current regulatory status before prescribing.
NCCN: Atezolizumab + nab-paclitaxel no longer recommended. Pembrolizumab + chemo preferred for PD-L1+ (CPS ≥10) 1L mTNBC [3].
⚡ Grey Zones
- OS failed to reach significance in ITT, preventing formal testing of the large PD-L1+ OS difference (HR 0.62)
- Benefit appears specific to nab-paclitaxel (IMpassion131 with paclitaxel was negative) — mechanism unknown
- PD-L1–negative patients showed no PFS benefit (HR 0.95) — alternative biomarkers needed
- Patients with bone metastases showed no benefit (HR 1.02)
- Untreated CNS disease was excluded
📖 Full Analysis
Read the complete desktop article with full efficacy tables, safety detail, subgroup data, comparator trials, and clinical implications at kill-cancer.com
About the Author
Andrew Stevenson is the founder and systems architect of kill-cancer.com. He holds 17 Google technical certifications in data systems, automation, and applied AI — the engineering foundation behind the extraction and verification pipeline that produces every article on this platform. Every number traces to its source publication. Zero calculation. Zero editorializing. Zero hallucination. Five siblings lost to cancer built the urgency. The engineering builds the trust.
📧 andrew@kill-cancer.com 🌐 kill-cancer.com 💬 kill-cancer.com/forum
For healthcare professionals only. Not medical advice. Trial results are presented as reported in the source publication. Updated data, label changes, or guideline revisions published after the source article may alter clinical applicability. Consult FDA labeling, NCCN guidelines, and institutional protocols.
References
- Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379:2108-2121. doi:10.1056/NEJMoa1809615
- Tecentriq (atezolizumab) prescribing information. U.S. Food and Drug Administration. Accessed March 2026.
- NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 2.2026. Accessed March 2026.
- Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355). Lancet. 2020;396:1817-1828. doi:10.1016/S0140-6736(20)32531-9
- Miles D, Gligorov J, André F, et al. Primary results from IMpassion131. Ann Oncol. 2021;32:994-1004. doi:10.1016/j.annonc.2021.05.801